BioSig Awarded US Patent Claims for its PURE EP™ Noise-Filtering Technology
January 26 2022 - 1:00PM
- Claims address computer-implemented systems and
methods for filtering noise from input cardiac
signals using its PURE EP™ technology
- The Company now has 49 issued or allowed worldwide
patents covering its novel technology for arrhythmia
care
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the US Patent Office had allowed a
utility patent covering its PURE EP™ noise-filtering
technology. The recently allowed patent application number
17/091,357 entitled “Universal Notch Filter" was filed on November
6, 2020. The patent describes and claims computer-implemented
methods for filtering noise from an input signal.
Generally, some current electrophysiology (EP) recording systems
can effectively support the treatment of arrhythmias such as atrial
flutter and supraventricular tachycardia, which show up as
large-amplitude, low-frequency signals. However, more complex and
prevalent arrhythmias, such as atrial fibrillation and ventricular
tachycardia, which are characterized by low-amplitude,
high-frequency signals, have not found an effective evaluation of
all relevant signals. This signal detection, acquisition, and
isolation can be further complicated by equipment line noise and
pacing signals. Current EP recorders use low-pass, high-pass, and
notch filters to remove noise and artifacts from the various
electrical signal information. Unfortunately, conventional
filtering techniques can alter signals and make it difficult or
impossible to see low-amplitude, high-frequency signals that can be
inherent in cardiac monitoring, the visualization of which signals
could help treat atrial fibrillation and ventricular tachycardia.
It has been recently recognized that the assurance of waveform
integrity, such as for the noise-free acquisition of IC and ECG
signals in an EP environment, had not been previously accomplished
due to contamination of various signals by artifacts and noise.
The patented PURE EP™ System can record raw (unaltered) cardiac
and other physiologic signals with multiple display options, low
noise, and a large input signal dynamic range. This is achieved
using a low-noise amplifier topology with minimal filtering to
band-limit the signal and a high-resolution A/D converter. In
addition, the PURE EP™ System can provide large-signal (e.g., from
a defibrillator) input protection and radio frequency (RF) signal
(e.g., from ablation) noise suppression. There is no need for gain
switching in this architecture, and the full range of input signals
is digitized with high resolution.
"We are pleased to announce this newest patent allowance which
demonstrates the clinical significance of our PURE EP™ System in
filtering noise from complex signals in the EP setting,” commented
Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies,
Inc. “We believe we have the leading patent-protected
solution for providing superior intracardiac signal information to
electrophysiologists during catheter ablation procedures across all
types of cardiac arrhythmias.”
One in 18 Americans suffers from a cardiac arrhythmia. Atrial
fibrillation is the most common arrhythmia type, affecting over 33
million people worldwide, including over 6 million in the U.S. The
number of people suffering from atrial fibrillation is expected to
reach 8-12 million by 20501. According to the Centers for
Disease Control and Prevention (CDC), atrial fibrillation causes
more than 750,000 hospitalizations in the U.S. each year, resulting
in approximately $6 billion in healthcare spending annually2.
About BioSig Technologies BioSig Technologies is a
medical technology company commercializing a proprietary biomedical
signal processing platform designed to improve signal fidelity and
uncover the full range of ECG and intra-cardiac signals
(www.biosig.com).
The Company’s first product, PURE EP™ System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording, and storing
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Top 10 Things You should Know About Heart Rhythm; Scripps
Health.
2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical
Economics Journal, February 25, 2019, Volume 96, Issue 4
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024